Medical Oncology, Год журнала: 2023, Номер 40(11)
Опубликована: Окт. 19, 2023
Язык: Английский
Biomaterials, Год журнала: 2024, Номер 314, С. 122856 - 122856
Опубликована: Сен. 28, 2024
Язык: Английский
Процитировано
4
Human Vaccines & Immunotherapeutics, Год журнала: 2025, Номер 21(1)
Опубликована: Янв. 27, 2025
This bibliometric and visualization study provides a comprehensive analysis of global research hotspots trends in DNA vaccine from 2014 to 2024. By employing data sourced the Web Science Core Collection, we identified total 3,600 articles. Our reveals declining trend annual publications. Active countries, institutions, journals, authors were identified, with China, Pasteur Network, Vaccine Journal, David B Weiner being most prolific contributors. Keywords cluster distinguished four major directions: infectious disease immunity, viral challenge development, optimization delivery systems, cancer immunotherapy research. The literature co-citation revealed hotspots, including vaccines for Zika virus, human papillomavirus (HPV), COVID-19, as well safety, efficacy, immunogenicity studies vaccines. Concurrently, burst citation emerging themes, development Ebola, MERS-CoV, innovations antigen design technologies. offers valuable insights into evolution future directions research, emphasizing its importance public health potential address current challenges.
Язык: Английский
Процитировано
0
Frontiers in Immunology, Год журнала: 2025, Номер 16
Опубликована: Янв. 31, 2025
Oncogenic forms of HPV account for 4.5% the global cancer burden worldwide. This includes cervical, vaginal, vulvar, penile, and anal cancers, as well head neck cancers. As such, there is an urgent need to develop effective therapeutic vaccines drive immune system's cellular response against cells. One primary goals vaccination increase potency diversity anti-tumor T-cell responses; one strategy do so involves delivery full-length antigens scaffolded onto DNA-launched nanoparticles improve priming. We developed a platform, making use structural prediction algorithms such AlphaFold2, design stabilized, more relevant proteins then display them on nanoparticles. demonstrated that many designs both HPV16 E6 E7 assembled drove strong CD8+ responses in mice. further tested genetically diverse, translationally CD-1 mouse model nanoparticle biased response. These findings serve proof-of-concept study antigen identify new vaccine candidates HPV-associated
Язык: Английский
Процитировано
0
Pharmaceutics, Год журнала: 2025, Номер 17(2), С. 216 - 216
Опубликована: Фев. 7, 2025
Cancer is one of the leading causes morbidity and mortality globally, responsible for approximately 10 million deaths in 2022 an estimated 21 new cases 2024. Traditional cancer treatments such as surgery, radiation therapy, chemotherapy often present limitations efficacy side effects. However, immunotherapeutic vaccines have emerged a promising approach, leveraging body’s immune system to target eliminate cells. This review examines evolving landscape vaccines, differentiating between preventive therapeutic strategies highlighting significance tumor-specific antigens, including tumor-associated antigens (TAAs) neoantigens. Recent advancements vaccine technology, particularly through nanotechnology, resulted development nanovaccines, which enhance antigen stability, optimize delivery cells, promote robust responses. Notably, clinical data indicate that patients receiving checkpoint inhibitors can achieve overall survival rates 34.8 months compared just 15.7 traditional therapies. Despite these advancements, challenges remain, immunosuppressive tumor microenvironment heterogeneity. Emerging evidence suggests combining nanovaccines with immunomodulators may by overcoming obstacles. Continued research interdisciplinary collaboration will be essential fully exploit promise ultimately more effective accessible patients. The future immunotherapy appears increasingly hopeful innovative pave way enhanced patient outcomes improved quality life oncology.
Язык: Английский
Процитировано
0
Vaccines, Год журнала: 2025, Номер 13(3), С. 237 - 237
Опубликована: Фев. 25, 2025
Immunotherapy is an established and efficient treatment strategy for a variety of malignancies. It aims to boost the anticancer properties one’s own immune system. Several immunotherapeutic options are available, but checkpoint blockers represent most widely known investigated. Anticancer vaccines evolving area immunotherapy that stimulate antigen-presenting cells, cytotoxic responses CD8+ T presence memory among others. Over years, different approaches have been studied, such as mRNA DNA vaccines, together with dendritic cell- viral vector-based vaccines. Recently, accumulating number clinical studies performed analyze safety potential efficacy these agents. The aim this review summarize recent advances regarding types therapeutic Furthermore, it will discuss how in preclinical models can enhance outcomes.
Язык: Английский
Процитировано
0
Cancers, Год журнала: 2025, Номер 17(6), С. 1008 - 1008
Опубликована: Март 17, 2025
Cancer, characterized by the uncontrolled proliferation of cells, is one leading causes death globally, with approximately in five people developing disease their lifetime. While many driver genes were identified decades ago, and most cancers can be classified based on morphology progression, there still a significant gap knowledge about genetic aberrations nuclear DNA damage. The study two critical groups genes—tumor suppressors, which inhibit promote apoptosis, oncogenes, regulate survival—can help to understand genomic behind tumorigenesis, more personalized approaches diagnosis treatment. Aberration tumor undergo two-hit loss-of-function mutations, activated forms proto-oncogenes that experience one-hit gain-of-function are responsible for dysregulation key signaling pathways cell division, such as p53, Rb, Ras/Raf/ERK/MAPK, PI3K/AKT, Wnt/β-catenin. Modern breakthroughs genomics research, like next-generation sequencing, have provided efficient strategies mapping unique changes contribute heterogeneity. Novel therapeutic enabled medicine, helping address variability suppressors oncogenes. This comprehensive review examines molecular mechanisms tumor-suppressor they regulate, epigenetic modifications, heterogeneity, drug resistance drive carcinogenesis. Moreover, explores clinical application sequencing techniques, multiomics, diagnostic procedures, pharmacogenomics, treatment prevention options, discussing future directions emerging technologies.
Язык: Английский
Процитировано
0
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0
BMEMat, Год журнала: 2025, Номер unknown
Опубликована: Март 26, 2025
Abstract Recent strides in non‐invasive drug delivery have spurred innovation alternatives to traditional needle injections. Transdermal systems (TDDs) emerged as a particularly promising avenue, boasting minimal rejection rates, user‐friendly administration, and enhanced patient adherence. Beyond pharmaceuticals, TDDs show potential skincare cosmetics, leveraging their ability facilitate localized while minimizing systemic exposure. Nonetheless, the intricate physicochemical nature of skin presents formidable obstacles, prompting intensive exploration overcome these barriers. This comprehensive review delves into landscape methodologies, critically analyzing respective advantages, limitations, characterization prospective applications. advancements underscore robust efficacy TDDs, positioning it versatile indispensable modality poised for widespread integration across multifarious fields.
Язык: Английский
Процитировано
0
Journal of Translational Medicine, Год журнала: 2025, Номер 23(1)
Опубликована: Апрель 15, 2025
Cancer immunotherapy aims to harness the body's own immune system for effective and long-lasting elimination of malignant neoplastic tissues. Owing advance in understanding cancer pathology immunology, many novel strategies enhancing immunological responses against various cancers have been successfully developed, some translated into excellent clinical outcomes. As one promising strategy next generation immunotherapies, activating multi-cellular network (MCN) within tumor microenvironment (TME) deploy multiple mechanisms action (MOAs) has attracted significant attention. To achieve this effectively safely, delivering or pleiotropic therapeutic cargoes targeted sites cancerous tissues, cells, intracellular organelles is critical, which numerous nanocarriers developed leveraged. In review, we first introduce payloads categorized according their predicted functions physicochemical structures forms. Then, nanocarriers, along with unique characteristics, properties, advantages, limitations, are introduced notable recent applications immunotherapy. Following discussions on targeting strategies, a summary each nanocarrier matching suitable provided comprehensive background information designing regimens.
Язык: Английский
Процитировано
0
Seminars in Oncology, Год журнала: 2025, Номер 52(3), С. 152345 - 152345
Опубликована: Апрель 29, 2025
Язык: Английский
Процитировано
0